IgA nephropathy, also known as Berger’s disease, is a condition where the immunoglobulin A (IgA) protein builds up in the kidneys and causes inflammation. The condition can worsen over time, leading to kidney failure, which can shorten life expectancy.
A study from the United States found that people with IgA nephropathy lived about 10 years fewer than expected. The average age of death was around 66 years, compared to 76 years in the general population.
The impact on life expectancy can vary depending on where you live and your background. For instance, in Sweden, research found that people with IgA nephropathy lived about six fewer years than the general population. The risk of death was highest in the first year after diagnosis, and most deaths occurred after kidney failure developed.
It’s important to remember that these numbers are averages from large groups of people. Your individual outlook depends on many factors, including if and when kidney failure, also called end-stage renal disease, develops. About 1 in 4 people with IgA nephropathy develop kidney failure within 10 years. Many experience kidney failure in their 40s and 50s, which can shorten life expectancy.
Several factors can influence how IgA nephropathy affects life expectancy. Some you can control, while others you cannot:
IgA nephropathy gradually progresses, but it doesn’t follow the same timeline for everyone. In some people, the progression is slow and steady, and they may live for years without serious complications. For others, the disease can worsen much faster, with kidney failure developing in just a few months.
In the early stages, you might not notice any symptoms. Instead, many people are diagnosed during routine tests that show protein or blood in the urine.
As IgA nephropathy progresses, inflammation in the kidneys can lead to a decline in kidney function. You may experience symptoms like:
If the disease progresses to end-stage renal disease, symptoms may include:
Predicting how fast IgA nephropathy will progress is one of the biggest challenges doctors face. They rely on kidney function tests, urine protein levels, and kidney biopsy results to help estimate risk, but these tools aren’t perfect. New research is looking at better ways to track progression, like blood or urine markers and imaging tools.
Treatments can help slow the progression, but there’s no cure for IgA nephropathy.
Typical treatment: ACE inhibitors and ARBs, are often the first line of defense. These medications help lower the pressure inside the kidneys and reduce protein loss in the urine, which can help slow damage. Lifestyle changes also play an important role in managing the disease and potentially slowing its progression.
Other treatments: In some cases, immunosuppressants and steroids may be used if the disease is progressing quickly. Some specialists prescribe statin medications to help protect the heart and blood vessels. If kidney function becomes severely reduced, dialysis (a machine that filters the blood) or a kidney transplant may be needed.
The future of treatment: New therapies that target different phases of the disease process are also being studied, which may help improve outcomes for people living with IgA nephropathy. Talk to your doctor about available clinical trials.
A diagnosis of IgA nephropathy can come with a lot of unknowns, especially early on. While this condition is serious, many people find ways to cope and maintain a good quality of life. You can try the following strategies to get support and improve your quality of life:
Wellness360 by Dr. Garg delivers the latest health news and wellness updates—curated from trusted global sources. We simplify medical research, trends, and breakthroughs so you can stay informed without the overwhelm. No clinics, no appointments—just reliable, doctor-reviewed health insights to guide your wellness journey